Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/USP47_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/USP47_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/USP47_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/USP47_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/USP47_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/USP47_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/USP47_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/USP47_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/USP47_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/USP47_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:2001233112 | Skin | SCCIS | regulation of apoptotic signaling pathway | 51/919 | 356/18723 | 5.51e-12 | 7.43e-09 | 51 |
GO:0097193112 | Skin | SCCIS | intrinsic apoptotic signaling pathway | 42/919 | 288/18723 | 2.40e-10 | 2.12e-07 | 42 |
GO:2001242112 | Skin | SCCIS | regulation of intrinsic apoptotic signaling pathway | 28/919 | 164/18723 | 7.32e-09 | 2.95e-06 | 28 |
GO:001605519 | Skin | SCCIS | Wnt signaling pathway | 51/919 | 444/18723 | 1.48e-08 | 4.37e-06 | 51 |
GO:019873819 | Skin | SCCIS | cell-cell signaling by wnt | 51/919 | 446/18723 | 1.72e-08 | 4.81e-06 | 51 |
GO:003011119 | Skin | SCCIS | regulation of Wnt signaling pathway | 41/919 | 328/18723 | 3.79e-08 | 7.72e-06 | 41 |
GO:0009314110 | Skin | SCCIS | response to radiation | 50/919 | 456/18723 | 9.08e-08 | 1.27e-05 | 50 |
GO:2001234112 | Skin | SCCIS | negative regulation of apoptotic signaling pathway | 30/919 | 224/18723 | 5.83e-07 | 4.62e-05 | 30 |
GO:0045861112 | Skin | SCCIS | negative regulation of proteolysis | 40/919 | 351/18723 | 6.58e-07 | 5.13e-05 | 40 |
GO:006007018 | Skin | SCCIS | canonical Wnt signaling pathway | 36/919 | 303/18723 | 8.82e-07 | 6.24e-05 | 36 |
GO:0016049111 | Skin | SCCIS | cell growth | 49/919 | 482/18723 | 1.17e-06 | 7.78e-05 | 49 |
GO:006082819 | Skin | SCCIS | regulation of canonical Wnt signaling pathway | 31/919 | 253/18723 | 2.62e-06 | 1.28e-04 | 31 |
GO:0052547112 | Skin | SCCIS | regulation of peptidase activity | 46/919 | 461/18723 | 4.09e-06 | 1.82e-04 | 46 |
GO:0071214110 | Skin | SCCIS | cellular response to abiotic stimulus | 36/919 | 331/18723 | 6.89e-06 | 2.67e-04 | 36 |
GO:0104004110 | Skin | SCCIS | cellular response to environmental stimulus | 36/919 | 331/18723 | 6.89e-06 | 2.67e-04 | 36 |
GO:0052548112 | Skin | SCCIS | regulation of endopeptidase activity | 43/919 | 432/18723 | 8.92e-06 | 3.22e-04 | 43 |
GO:2001243112 | Skin | SCCIS | negative regulation of intrinsic apoptotic signaling pathway | 16/919 | 98/18723 | 2.14e-05 | 6.32e-04 | 16 |
GO:0051346111 | Skin | SCCIS | negative regulation of hydrolase activity | 38/919 | 379/18723 | 2.49e-05 | 6.97e-04 | 38 |
GO:007147817 | Skin | SCCIS | cellular response to radiation | 23/919 | 186/18723 | 4.31e-05 | 1.08e-03 | 23 |
GO:0010951110 | Skin | SCCIS | negative regulation of endopeptidase activity | 28/919 | 252/18723 | 4.82e-05 | 1.18e-03 | 28 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
USP47 | SNV | Missense_Mutation | rs754155092 | c.2314N>T | p.Arg772Cys | p.R772C | Q96K76 | protein_coding | deleterious(0) | probably_damaging(0.965) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
USP47 | SNV | Missense_Mutation | | c.3127N>C | p.Glu1043Gln | p.E1043Q | Q96K76 | protein_coding | tolerated(0.25) | benign(0.047) | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
USP47 | SNV | Missense_Mutation | novel | c.81N>C | p.Met27Ile | p.M27I | Q96K76 | protein_coding | tolerated_low_confidence(0.19) | benign(0) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
USP47 | SNV | Missense_Mutation | | c.4046G>A | p.Arg1349His | p.R1349H | Q96K76 | protein_coding | tolerated(0.09) | benign(0) | TCGA-BH-A18F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
USP47 | SNV | Missense_Mutation | | c.3865C>T | p.His1289Tyr | p.H1289Y | Q96K76 | protein_coding | deleterious(0.01) | benign(0.101) | TCGA-C8-A12Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
USP47 | SNV | Missense_Mutation | | c.2879N>G | p.Asp960Gly | p.D960G | Q96K76 | protein_coding | tolerated(0.06) | probably_damaging(0.971) | TCGA-D8-A27I-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adrimycin+cyclophosphamide | SD |
USP47 | SNV | Missense_Mutation | | c.1726N>C | p.Asp576His | p.D576H | Q96K76 | protein_coding | tolerated(0.1) | benign(0) | TCGA-EW-A1P4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
USP47 | SNV | Missense_Mutation | novel | c.3742G>C | p.Glu1248Gln | p.E1248Q | Q96K76 | protein_coding | deleterious(0.04) | probably_damaging(0.954) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
USP47 | insertion | Frame_Shift_Ins | novel | c.3125_3126insGTCCCTC | p.Asp1042GlufsTer4 | p.D1042Efs*4 | Q96K76 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
USP47 | SNV | Missense_Mutation | novel | c.1153N>A | p.Leu385Met | p.L385M | Q96K76 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |